Analysis and Prospect of pharmaceutical market in 2015 (R & D)

Source: Biovalley 2015-06-24 Gilead triple therapy has become the most valuable R & D project in the world The net present value (NPV) of R & D projects in the pharmaceutical industry is 493 billion US dollars, and Gilead combined therapy for hepatitis C has the highest value It is found that the total NPV of R & D increased by 18% from US $418.5 billion to US $492.8 billion Gilead triple hepatitis C therapy gs-9857 / sof / gs-5816 has become the most valuable R & D product with a total value of US $24.8 billion Eight of the 20 R & D projects with the highest NPV last year have been approved Since June 2014, the NPV has increased by 85%, creating a total value of US $129.2 billion The productivity of pharmaceutical research and development is on the rise The global R & D cost of the most valuable R & D project TOP10 continues to rise by 2.0% and will reach US $160 billion in 2020 In 2014, global R & D costs totaled US $141.6 billion, up 3.1% from the previous year The average growth rate from 2006 to 2014 is 3.4%, which is expected to grow at an annual rate of 2.0% in the future Each new molecular entity (NME) is developed and approved at an interval of 3 years In 2014, the average R & D cost per new molecular entity was $2.7 billion, a new low in the past seven years Statistics of global R & D expenses (2006-2020) in 2020, Novartis R & D investment still ranks first, and Novartis is still the company with the highest R & D investment in the world It is estimated that in 2020, Novartis will invest US $10.5 billion Among the 20 companies with the highest R & D expenses, celgene, the giant, has the fastest growth, with an average annual increase of 10%, and will reach 3.3 billion US dollars in 2020 The industry's R & D costs will increase by an average of 2.0% per year and reach US $159.8 billion in 2020 In 2020, the number of top 10 FDA new drugs approved by the enterprise has reached a new high The 50 new drugs approved by the FDA in 2014 include 30 new molecular entities and 20 biotechnological drugs Five years after the drug was approved for marketing in the United States, total sales rose 43% to $26.1 billion, with an average of $522 million per approved drug Bristol Myers Squibb opdivo is the first approved drug in 2014, with sales expected to reach $4.3 billion in 2019 Sales of drugs five years after approval